The global market for Chronic Liver Diseases Therapeutics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Chronic Liver Diseases Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Chronic Liver Diseases Therapeutics by region & country, by Type, and by Application.

The Chronic Liver Diseases Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Liver Diseases Therapeutics.

Market Segmentation

Scope of Chronic Liver Diseases Therapeutics - Market Report

Report Metric	Details
Report Name	Chronic Liver Diseases Therapeutics - Market
CAGR	5%
Segment by Type:	Chemotherapy Drugs Targeted Therapy Vaccines Antiviral Drugs Immunoglobulins Corticosteroids Others
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Astellas Pharma, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, F. Hoffmann-La Roche, Merck, Novartis, Sanofi, Pfizer, Takeda Pharmaceutical, Bausch Health, Theratechnologies, Alnylam Pharmaceuticals, Protagonist Therapeutics, Dicerna Pharmaceuticals, Endo International, Provectus Biopharmaceuticals, MAX BioPharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Chronic Liver Diseases Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Chronic Liver Diseases Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Chronic Liver Diseases Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Chronic Liver Diseases Therapeutics - Market report?

Ans: The main players in the Chronic Liver Diseases Therapeutics - Market are Astellas Pharma, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, F. Hoffmann-La Roche, Merck, Novartis, Sanofi, Pfizer, Takeda Pharmaceutical, Bausch Health, Theratechnologies, Alnylam Pharmaceuticals, Protagonist Therapeutics, Dicerna Pharmaceuticals, Endo International, Provectus Biopharmaceuticals, MAX BioPharma

What are the Application segmentation covered in the Chronic Liver Diseases Therapeutics - Market report?

Ans: The Applications covered in the Chronic Liver Diseases Therapeutics - Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Chronic Liver Diseases Therapeutics - Market report?

Ans: The Types covered in the Chronic Liver Diseases Therapeutics - Market report are Chemotherapy Drugs, Targeted Therapy, Vaccines, Antiviral Drugs, Immunoglobulins, Corticosteroids, Others

1 Market Overview

1.1 Chronic Liver Diseases Therapeutics Product Introduction

1.2 Global Chronic Liver Diseases Therapeutics Market Size Forecast

1.3 Chronic Liver Diseases Therapeutics Market Trends & Drivers

1.3.1 Chronic Liver Diseases Therapeutics Industry Trends

1.3.2 Chronic Liver Diseases Therapeutics Market Drivers & Opportunity

1.3.3 Chronic Liver Diseases Therapeutics Market Challenges

1.3.4 Chronic Liver Diseases Therapeutics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Chronic Liver Diseases Therapeutics Players Revenue Ranking (2023)

2.2 Global Chronic Liver Diseases Therapeutics Revenue by Company (2019-2024)

2.3 Key Companies Chronic Liver Diseases Therapeutics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Chronic Liver Diseases Therapeutics Product Offered

2.5 Key Companies Time to Begin Mass Production of Chronic Liver Diseases Therapeutics

2.6 Chronic Liver Diseases Therapeutics Market Competitive Analysis

2.6.1 Chronic Liver Diseases Therapeutics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Chronic Liver Diseases Therapeutics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Liver Diseases Therapeutics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Chemotherapy Drugs

3.1.2 Targeted Therapy

3.1.3 Vaccines

3.1.4 Antiviral Drugs

3.1.5 Immunoglobulins

3.1.6 Corticosteroids

3.1.7 Others

3.2 Global Chronic Liver Diseases Therapeutics Sales Value by Type

3.2.1 Global Chronic Liver Diseases Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Chronic Liver Diseases Therapeutics Sales Value, by Type (2019-2030)

3.2.3 Global Chronic Liver Diseases Therapeutics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital Pharmacies

4.1.2 Retail Pharmacies

4.1.3 Online Pharmacies

4.2 Global Chronic Liver Diseases Therapeutics Sales Value by Application

4.2.1 Global Chronic Liver Diseases Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Chronic Liver Diseases Therapeutics Sales Value, by Application (2019-2030)

4.2.3 Global Chronic Liver Diseases Therapeutics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Chronic Liver Diseases Therapeutics Sales Value by Region

5.1.1 Global Chronic Liver Diseases Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Chronic Liver Diseases Therapeutics Sales Value by Region (2019-2024)

5.1.3 Global Chronic Liver Diseases Therapeutics Sales Value by Region (2025-2030)

5.1.4 Global Chronic Liver Diseases Therapeutics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Chronic Liver Diseases Therapeutics Sales Value, 2019-2030

5.2.2 North America Chronic Liver Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Chronic Liver Diseases Therapeutics Sales Value, 2019-2030

5.3.2 Europe Chronic Liver Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Chronic Liver Diseases Therapeutics Sales Value, 2019-2030

5.4.2 Asia Pacific Chronic Liver Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Chronic Liver Diseases Therapeutics Sales Value, 2019-2030

5.5.2 South America Chronic Liver Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Chronic Liver Diseases Therapeutics Sales Value, 2019-2030

5.6.2 Middle East & Africa Chronic Liver Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Chronic Liver Diseases Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Chronic Liver Diseases Therapeutics Sales Value

6.3 United States

6.3.1 United States Chronic Liver Diseases Therapeutics Sales Value, 2019-2030

6.3.2 United States Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Chronic Liver Diseases Therapeutics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Chronic Liver Diseases Therapeutics Sales Value, 2019-2030

6.4.2 Europe Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Chronic Liver Diseases Therapeutics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Chronic Liver Diseases Therapeutics Sales Value, 2019-2030

6.5.2 China Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

6.5.3 China Chronic Liver Diseases Therapeutics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Chronic Liver Diseases Therapeutics Sales Value, 2019-2030

6.6.2 Japan Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Chronic Liver Diseases Therapeutics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Chronic Liver Diseases Therapeutics Sales Value, 2019-2030

6.7.2 South Korea Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Chronic Liver Diseases Therapeutics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Chronic Liver Diseases Therapeutics Sales Value, 2019-2030

6.8.2 Southeast Asia Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Chronic Liver Diseases Therapeutics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Chronic Liver Diseases Therapeutics Sales Value, 2019-2030

6.9.2 India Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

6.9.3 India Chronic Liver Diseases Therapeutics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Astellas Pharma

7.1.1 Astellas Pharma Profile

7.1.2 Astellas Pharma Main Business

7.1.3 Astellas Pharma Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.1.4 Astellas Pharma Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.1.5 Astellas Pharma Recent Developments

7.2 Bristol-Myers Squibb

7.2.1 Bristol-Myers Squibb Profile

7.2.2 Bristol-Myers Squibb Main Business

7.2.3 Bristol-Myers Squibb Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.2.4 Bristol-Myers Squibb Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.2.5 Bristol-Myers Squibb Recent Developments

7.3 Gilead Sciences

7.3.1 Gilead Sciences Profile

7.3.2 Gilead Sciences Main Business

7.3.3 Gilead Sciences Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.3.4 Gilead Sciences Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.3.5 GlaxoSmithKline Recent Developments

7.4 GlaxoSmithKline

7.4.1 GlaxoSmithKline Profile

7.4.2 GlaxoSmithKline Main Business

7.4.3 GlaxoSmithKline Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.4.4 GlaxoSmithKline Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.4.5 GlaxoSmithKline Recent Developments

7.5 F. Hoffmann-La Roche

7.5.1 F. Hoffmann-La Roche Profile

7.5.2 F. Hoffmann-La Roche Main Business

7.5.3 F. Hoffmann-La Roche Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.5.4 F. Hoffmann-La Roche Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.5.5 F. Hoffmann-La Roche Recent Developments

7.6 Merck

7.6.1 Merck Profile

7.6.2 Merck Main Business

7.6.3 Merck Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.6.4 Merck Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.6.5 Merck Recent Developments

7.7 Novartis

7.7.1 Novartis Profile

7.7.2 Novartis Main Business

7.7.3 Novartis Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.7.4 Novartis Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.7.5 Novartis Recent Developments

7.8 Sanofi

7.8.1 Sanofi Profile

7.8.2 Sanofi Main Business

7.8.3 Sanofi Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.8.4 Sanofi Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.8.5 Sanofi Recent Developments

7.9 Pfizer

7.9.1 Pfizer Profile

7.9.2 Pfizer Main Business

7.9.3 Pfizer Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.9.4 Pfizer Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.9.5 Pfizer Recent Developments

7.10 Takeda Pharmaceutical

7.10.1 Takeda Pharmaceutical Profile

7.10.2 Takeda Pharmaceutical Main Business

7.10.3 Takeda Pharmaceutical Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.10.4 Takeda Pharmaceutical Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.10.5 Takeda Pharmaceutical Recent Developments

7.11 Bausch Health

7.11.1 Bausch Health Profile

7.11.2 Bausch Health Main Business

7.11.3 Bausch Health Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.11.4 Bausch Health Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.11.5 Bausch Health Recent Developments

7.12 Theratechnologies

7.12.1 Theratechnologies Profile

7.12.2 Theratechnologies Main Business

7.12.3 Theratechnologies Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.12.4 Theratechnologies Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.12.5 Theratechnologies Recent Developments

7.13 Alnylam Pharmaceuticals

7.13.1 Alnylam Pharmaceuticals Profile

7.13.2 Alnylam Pharmaceuticals Main Business

7.13.3 Alnylam Pharmaceuticals Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.13.4 Alnylam Pharmaceuticals Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.13.5 Alnylam Pharmaceuticals Recent Developments

7.14 Protagonist Therapeutics

7.14.1 Protagonist Therapeutics Profile

7.14.2 Protagonist Therapeutics Main Business

7.14.3 Protagonist Therapeutics Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.14.4 Protagonist Therapeutics Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.14.5 Protagonist Therapeutics Recent Developments

7.15 Dicerna Pharmaceuticals

7.15.1 Dicerna Pharmaceuticals Profile

7.15.2 Dicerna Pharmaceuticals Main Business

7.15.3 Dicerna Pharmaceuticals Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.15.4 Dicerna Pharmaceuticals Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.15.5 Dicerna Pharmaceuticals Recent Developments

7.16 Endo International

7.16.1 Endo International Profile

7.16.2 Endo International Main Business

7.16.3 Endo International Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.16.4 Endo International Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.16.5 Endo International Recent Developments

7.17 Provectus Biopharmaceuticals

7.17.1 Provectus Biopharmaceuticals Profile

7.17.2 Provectus Biopharmaceuticals Main Business

7.17.3 Provectus Biopharmaceuticals Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.17.4 Provectus Biopharmaceuticals Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.17.5 Provectus Biopharmaceuticals Recent Developments

7.18 MAX BioPharma

7.18.1 MAX BioPharma Profile

7.18.2 MAX BioPharma Main Business

7.18.3 MAX BioPharma Chronic Liver Diseases Therapeutics Products, Services and Solutions

7.18.4 MAX BioPharma Chronic Liver Diseases Therapeutics Revenue (US$ Million) & (2019-2024)

7.18.5 MAX BioPharma Recent Developments

8 Industry Chain Analysis

8.1 Chronic Liver Diseases Therapeutics Industrial Chain

8.2 Chronic Liver Diseases Therapeutics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Chronic Liver Diseases Therapeutics Sales Model

8.5.2 Sales Channel

8.5.3 Chronic Liver Diseases Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Takeda Pharmaceutical

Bausch Health

Theratechnologies

Alnylam Pharmaceuticals

Protagonist Therapeutics

Dicerna Pharmaceuticals

Endo International

Provectus Biopharmaceuticals

MAX BioPharma

List of Tables

Table 1. Chronic Liver Diseases Therapeutics Market Trends

Table 2. Chronic Liver Diseases Therapeutics Market Drivers & Opportunity

Table 3. Chronic Liver Diseases Therapeutics Market Challenges

Table 4. Chronic Liver Diseases Therapeutics Market Restraints

Table 5. Global Chronic Liver Diseases Therapeutics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Chronic Liver Diseases Therapeutics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Chronic Liver Diseases Therapeutics Product Type

Table 9. Key Companies Time to Begin Mass Production of Chronic Liver Diseases Therapeutics

Table 10. Global Chronic Liver Diseases Therapeutics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Liver Diseases Therapeutics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Chronic Liver Diseases Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Chronic Liver Diseases Therapeutics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Chronic Liver Diseases Therapeutics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Chronic Liver Diseases Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Chronic Liver Diseases Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Chronic Liver Diseases Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Chronic Liver Diseases Therapeutics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Chronic Liver Diseases Therapeutics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Chronic Liver Diseases Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Chronic Liver Diseases Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Chronic Liver Diseases Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Chronic Liver Diseases Therapeutics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Chronic Liver Diseases Therapeutics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Chronic Liver Diseases Therapeutics Sales Value by Region (2019-2024) & (%)

Table 27. Global Chronic Liver Diseases Therapeutics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Chronic Liver Diseases Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Chronic Liver Diseases Therapeutics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Chronic Liver Diseases Therapeutics Sales Value, (2025-2030) & (US$ Million)

Table 31. Astellas Pharma Basic Information List

Table 32. Astellas Pharma Description and Business Overview

Table 33. Astellas Pharma Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Astellas Pharma (2019-2024)

Table 35. Astellas Pharma Recent Developments

Table 36. Bristol-Myers Squibb Basic Information List

Table 37. Bristol-Myers Squibb Description and Business Overview

Table 38. Bristol-Myers Squibb Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Bristol-Myers Squibb (2019-2024)

Table 40. Bristol-Myers Squibb Recent Developments

Table 41. Gilead Sciences Basic Information List

Table 42. Gilead Sciences Description and Business Overview

Table 43. Gilead Sciences Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Gilead Sciences (2019-2024)

Table 45. Gilead Sciences Recent Developments

Table 46. GlaxoSmithKline Basic Information List

Table 47. GlaxoSmithKline Description and Business Overview

Table 48. GlaxoSmithKline Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of GlaxoSmithKline (2019-2024)

Table 50. GlaxoSmithKline Recent Developments

Table 51. F. Hoffmann-La Roche Basic Information List

Table 52. F. Hoffmann-La Roche Description and Business Overview

Table 53. F. Hoffmann-La Roche Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of F. Hoffmann-La Roche (2019-2024)

Table 55. F. Hoffmann-La Roche Recent Developments

Table 56. Merck Basic Information List

Table 57. Merck Description and Business Overview

Table 58. Merck Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Merck (2019-2024)

Table 60. Merck Recent Developments

Table 61. Novartis Basic Information List

Table 62. Novartis Description and Business Overview

Table 63. Novartis Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Novartis (2019-2024)

Table 65. Novartis Recent Developments

Table 66. Sanofi Basic Information List

Table 67. Sanofi Description and Business Overview

Table 68. Sanofi Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 69. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Sanofi (2019-2024)

Table 70. Sanofi Recent Developments

Table 71. Pfizer Basic Information List

Table 72. Pfizer Description and Business Overview

Table 73. Pfizer Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 74. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Pfizer (2019-2024)

Table 75. Pfizer Recent Developments

Table 76. Takeda Pharmaceutical Basic Information List

Table 77. Takeda Pharmaceutical Description and Business Overview

Table 78. Takeda Pharmaceutical Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 79. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Takeda Pharmaceutical (2019-2024)

Table 80. Takeda Pharmaceutical Recent Developments

Table 81. Bausch Health Basic Information List

Table 82. Bausch Health Description and Business Overview

Table 83. Bausch Health Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 84. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Bausch Health (2019-2024)

Table 85. Bausch Health Recent Developments

Table 86. Theratechnologies Basic Information List

Table 87. Theratechnologies Description and Business Overview

Table 88. Theratechnologies Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 89. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Theratechnologies (2019-2024)

Table 90. Theratechnologies Recent Developments

Table 91. Alnylam Pharmaceuticals Basic Information List

Table 92. Alnylam Pharmaceuticals Description and Business Overview

Table 93. Alnylam Pharmaceuticals Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 94. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Alnylam Pharmaceuticals (2019-2024)

Table 95. Alnylam Pharmaceuticals Recent Developments

Table 96. Protagonist Therapeutics Basic Information List

Table 97. Protagonist Therapeutics Description and Business Overview

Table 98. Protagonist Therapeutics Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 99. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Protagonist Therapeutics (2019-2024)

Table 100. Protagonist Therapeutics Recent Developments

Table 101. Dicerna Pharmaceuticals Basic Information List

Table 102. Dicerna Pharmaceuticals Description and Business Overview

Table 103. Dicerna Pharmaceuticals Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 104. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Dicerna Pharmaceuticals (2019-2024)

Table 105. Dicerna Pharmaceuticals Recent Developments

Table 106. Endo International Basic Information List

Table 107. Endo International Description and Business Overview

Table 108. Endo International Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 109. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Endo International (2019-2024)

Table 110. Endo International Recent Developments

Table 111. Provectus Biopharmaceuticals Basic Information List

Table 112. Provectus Biopharmaceuticals Description and Business Overview

Table 113. Provectus Biopharmaceuticals Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 114. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of Provectus Biopharmaceuticals (2019-2024)

Table 115. Provectus Biopharmaceuticals Recent Developments

Table 116. MAX BioPharma Basic Information List

Table 117. MAX BioPharma Description and Business Overview

Table 118. MAX BioPharma Chronic Liver Diseases Therapeutics Products, Services and Solutions

Table 119. Revenue (US$ Million) in Chronic Liver Diseases Therapeutics Business of MAX BioPharma (2019-2024)

Table 120. MAX BioPharma Recent Developments

Table 121. Key Raw Materials Lists

Table 122. Raw Materials Key Suppliers Lists

Table 123. Chronic Liver Diseases Therapeutics Downstream Customers

Table 124. Chronic Liver Diseases Therapeutics Distributors List

Table 125. Research Programs/Design for This Report

Table 126. Key Data Information from Secondary Sources

Table 127. Key Data Information from Primary Sources

Table 128. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Chronic Liver Diseases Therapeutics Product Picture

Figure 2. Global Chronic Liver Diseases Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Chronic Liver Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 4. Chronic Liver Diseases Therapeutics Report Years Considered

Figure 5. Global Chronic Liver Diseases Therapeutics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Chronic Liver Diseases Therapeutics Revenue in 2023

Figure 7. Chronic Liver Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Chemotherapy Drugs Picture

Figure 9. Targeted Therapy Picture

Figure 10. Vaccines Picture

Figure 11. Antiviral Drugs Picture

Figure 12. Immunoglobulins Picture

Figure 13. Corticosteroids Picture

Figure 14. Others Picture

Figure 15. Global Chronic Liver Diseases Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global Chronic Liver Diseases Therapeutics Sales Value Market Share by Type, 2023 & 2030

Figure 17. Product Picture of Hospital Pharmacies

Figure 18. Product Picture of Retail Pharmacies

Figure 19. Product Picture of Online Pharmacies

Figure 20. Global Chronic Liver Diseases Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 21. Global Chronic Liver Diseases Therapeutics Sales Value Market Share by Application, 2023 & 2030

Figure 22. North America Chronic Liver Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 23. North America Chronic Liver Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 24. Europe Chronic Liver Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 25. Europe Chronic Liver Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 26. Asia Pacific Chronic Liver Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 27. Asia Pacific Chronic Liver Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 28. South America Chronic Liver Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 29. South America Chronic Liver Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 30. Middle East & Africa Chronic Liver Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 31. Middle East & Africa Chronic Liver Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 32. Key Countries/Regions Chronic Liver Diseases Therapeutics Sales Value (%), (2019-2030)

Figure 33. United States Chronic Liver Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 34. United States Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 35. United States Chronic Liver Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 36. Europe Chronic Liver Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 37. Europe Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 38. Europe Chronic Liver Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 39. China Chronic Liver Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 40. China Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 41. China Chronic Liver Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 42. Japan Chronic Liver Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 43. Japan Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 44. Japan Chronic Liver Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 45. South Korea Chronic Liver Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 46. South Korea Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 47. South Korea Chronic Liver Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 48. Southeast Asia Chronic Liver Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 49. Southeast Asia Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 50. Southeast Asia Chronic Liver Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 51. India Chronic Liver Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 52. India Chronic Liver Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 53. India Chronic Liver Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 54. Chronic Liver Diseases Therapeutics Industrial Chain

Figure 55. Chronic Liver Diseases Therapeutics Manufacturing Cost Structure

Figure 56. Channels of Distribution (Direct Sales, and Distribution)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions